NeoGenomics, Inc.

$12.29 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. It offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.

Stock Analysis

last close $12.29
1-mo return 44.4%
3-mo return 66.5%
avg daily vol. 2.27M
52-week high 54.74
52-week low 6.85
market cap. $1.3B
forward pe -
annual div. -
roe -3.7%
ltg forecast 1.3%
dividend yield -
annual rev. $486M
inst own. 92.7%
baraka

Subscribe now for daily local and international financial news

Subscribe